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SHORT COMMUNICATION
Near death from a novel synthetic opioid labeled U-47700: emergence of a new
opioid class
Aaron Schneira,b, Imir G. Metushic, Christian Sloaneb, David J. Benaronb and Robert L. Fitzgeraldc
aDivision of Medical Toxicology, University of California, San Diego Health System, San Diego, CA, USA; bDepartment of Emergency Medicine,
University of California, San Diego Health System, San Diego, CA, USA; cDepartment of Pathology, Center for Advanced Laboratory Medicine,
University of California, San Diego Health System, San Diego, CA, USA
ABSTRACT
Background: In the last decade there has been a worldwide surge in the recreational abuse of novel
psychoactive substances, particularly amphetamine derivatives and synthetic cannabinoids. Synthetic
opioids such as AH-7921, MT-45, and U-47700, with structures distinct from those ever used therapeut-
ically or described recreationally, have also recently emerged.
Case details: We report a patient who suffered respiratory failure and depressed level of consciousness
after recreationally using a novel synthetic opioid labeled U-47700. A single dose of naloxone adminis-
tered by paramedics completely reversed his opioid poisoning. Comprehensive laboratory analysis con-
firmed the presence of a novel synthetic opioid and excluded other drugs. The drug used appeared to
have caused a false positive benzodiazepine result on the initial urine drugs of abuse panel.
Conclusion: The case we describe of toxicity from the synthetic opioid labeled U-47700 highlights the
emerging trend of novel synthetic opioid abuse.
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Introduction
In the last decade there has been a worldwide surge in the
recreational abuse of novel psychoactive substances.
Although the most popular of these have been synthetic
amphetamine derivatives and synthetic cannabinoids,[1–3]
novel synthetic opioids have also surfaced.[4–11] Traditionally,
many novel synthetic opioids have been derivatives of thera-
peutically used drugs, primarily fentanyl and meperidine.[12]
The recent identification of acetylfentanyl, butyrfentanyl, and
4-fluorobutyrfentanyl as drugs of abuse represent a continu-
ation of this trend.[4,7,8] However, novel synthetic opioids
with structures distinct from those ever used therapeutically
or described recreationally have also recently emerged,
including AH-7921 [3,4-dichloro-N-[(1 dimethylamino) cyclo-
hexylmethyl] benzamide] (trans-1,2-diamine structure), MT-45
[1-cyclohexyl-4-(1,2-diphenylethyl)] (piperazine structure) and
U-47700 [trans-3,4-dichloro-N-(2-(dimethylamino) cyclohexyl)-
N-methylbenzamide] (trans-1,2-diamine structure).[5,6,9–11]
We report a patient who nearly died after recreationally abus-
ing a novel synthetic opioid labeled U-47700.
Case details
A 22-year-old male with a history of heroin abuse was found
unconscious and apneic by his mother. His mother contacted
emergency medical services and began to perform cardiopul-
monary resuscitation (CPR) (rescue breaths and chest com-
pressions) which she continued for four to five minutes until
paramedics arrived. Paramedics found the patient to be cyan-
otic, having agonal respirations they estimated at 4 per
minute and to have a room air pulse oximetry reading of
60%. The patient’s initial blood pressure was 138/88mmHg,
pulse 134 per minute, and he was comatose with a Glasgow
Coma Scale of 3. An oral pharyngeal airway was placed and
the patient’s respirations were assisted with a bag-valve mask
that improved his oxygen saturation to 90%. Two milligrams
of naloxone were administered intravenously which com-
pletely reversed his coma and bradypnea, and the patient
was transported to the emergency department (ED). Upon
presentation to the ED the patient’s only complaint was a
sore chest where chest compressions had been done and
that his head was feeling ‘‘foggy’’. His initial vital signs in the
ED were: blood pressure 112/71mmHg, pulse 92 per minute,
temperature 97.6 F (36.4 C), normal respirations, and pulse
oximetry 97% on room air. Physical examination revealed the
patient to be alert and oriented, to have normal sized and
reactive pupils, clear lungs, the absence of track marks, and
the presence of abrasions and tenderness over his sternum
where chest compressions had been performed. The patient
reported that just before being found by his mother, for rec-
reational purposes, he had used the opioid agonist U-47700
he had acquired over the internet. He described having pur-
chased what he interpreted as 250mg of the drug in powder
form which he divided into five separate doses. He described
having used the drug two times previously without adverse
effect. Each time he described placing the drug in a syringe,
mixing it with water and applying it to his nostrils. He was
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not on any prescribed medications and denied the recent use
of any other drugs.
A chest radiograph was normal, and an electrocardiogram
was unremarkable demonstrating a normal QRS width and a
QTc of 442ms. A routine chemistry was normal as was a com-
plete blood count except for a leukocytosis of 16,000/mm3
(reference range 4–10,000mm3); differential with 88% neutro-
phils, 8% lymphocytes, 2% monocytes, 1% eosinophils. The
patient was observed in the ED for approximately five hours
during which he had no respiratory depression or sedation.
No further naloxone was administered. A urine drugs of
abuse panel by immunoassay (Roche ONLINE DAT Plus per-
formed on a Cobas 6000 analyzer, Roche Diagnostics
International Ltd. Switzerland) was positive for benzodiaze-
pines as a class, but negative for amphetamines as a class,
barbiturates as a class, benzoylecgonine (cocaine metabolite),
methadone, opiates as a class, oxycodone, phencyclidine, and
tetrahydrocannabinoids. He was discharged home and when
contacted approximately a week later denied any symptoms.
The urine drugs of abuse panel by immunoassay uses nor-
diazepam at 100 ng/mL as a cutoff calibrator, but reacts with a
variety of other benzodiazepines. Confirmatory testing for ben-
zodiazepines in the urine by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) using a limit detection of 20 ng/
mL did not detect any of the following benzodiazepines and/or
their major metabolites: alprazolam, clonazepam, diazepam,
flurazepam, lorazepam, midazolam, oxazepam or temazepam.
Further analysis of urine was performed using a broad spec-
trum liquid chromatography time-of-flight (LC-TOF) high-reso-
lution mass spectrometry assay as previously described by
Chindarkar et al.[13] The urine specimen was negative for sixty-
one compounds that have been validated for this assay, and
further excluded the following opioids: buprenorphine, dextro-
methorphan, fentanyl, hydrocodone, hydromorphone, meperi-
dine, oxymorphone, propoxyphene, tapentadol, and tramadol.
The LC-TOF results confirmed the presence of a compound
with the molecular formula C16H22Cl2N2O in the patient’s
urine, which matches that of U-47700. The extracted ion chro-
matogram from the urine sample of the patient had identical
retention time and mass spectra with that of the powder he
provided for testing. Figure 1(A) shows an example chromato-
gram of the powder used which had predominant peaks at
5.25 and 5.36min. The mass spectrum of the peak at 5.36min
(Figure 1(B)) was within 3 ppm of the expected protonated
mass of U-47700 (329.1187). The mass spectrum of peak at
5.25min (Figure 1(C)) was within 3 ppm of the elemental for-
mula C15H20Cl2N2O consistent with a demethylated version of
U-47700 (protonated expected mass of 315.1031). The iso-
topic pattern of the molecular ions demonstrates that the
compounds contain two chlorines with Aþ 2 abundance of
about 66%. These compounds were also identified by LC-TOF
analysis of drug the patient provided. The powder supplied
by the patient had identical retention time and mass spectra
of the compounds found in the patient’s urine. We were
unable to obtain an authentic reference standard for U-47700
from a reliable source, but we were able to do so for AH-
7921 (Cayman Chemical, Ann Arbor, MI), which shares the
same molecular formula (but different structure). The pres-
ence of AH-7921 in the patient’s urine was excluded using
the LC-TOF platform because the authentic compound had a
different retention time (Figure 1(A)) and spectra (Figure
1(D)).
To determine if the drug our patient used could have
caused the false positive on the benzodiazepine immuno-
assay used, the powder the patient provided was added
to drug free urine at increasing amounts (from 1 lg/mL up to
25mg/mL) and tested using the benzodiazepine immuno-
assay. Table 1 shows the cross-reactivity of the substance the
patient used at varying concentrations. There was a dose
dependent increase in the signal with increasing concentra-
tions, but a positive immunoassay for benzodiazepines
occurred only at a very high concentration of 10mg/mL
(10,000mcg/mL). Given the high-concentration needed for
the parent drug to cause a positive benzodiazepine positive
result, and by history the relatively small amount of drug
used, it appears likely that an unknown metabolite of
U-47700 with more cross-reactivity than the parent drug may
have caused the false positive benzodiazepine result. It also
remains possible that the patient used a benzodiazepine not
tested for on our analysis.
Discussion
The patient described nearly died after recreationally abusing
a synthetic opioid sold as U-47700. He fortunately was resus-
citated quickly and appears to have suffered no permanent
sequelae. The toxicity he manifested (depressed level of con-
sciousness and respiratory depression) and its reversal with
naloxone administration is consistent with the known in vitro
and in vivo opioid agonism of U-47700.[14,15] We are not
aware of any metabolic or pharmacokinetic data on U-47700,
nor any literature detailing any therapeutic effects of U-47700
in humans. Two recently published cases detail the identifica-
tion of U-47700 postmortem and implicate its use in the
deaths.[10,11] We are also unaware of any pharmacokinetic
data on the similarly structured AH-7921. The short length of
time the patient experienced opioid toxicity suggests the
drug has a relatively short half-life. U-47700 is a l opioid
agonist that is one of many synthetic opioids in the trans-
1,2-diamine class that were developed in the 1970s at the
Upjohn Company by a chemist Jacob Szmuszkovicz.[16] The
‘‘U’’ in U-47700 refers to Upjohn. Drugs in this trans-
1,2-diamine class have a distinct structure from other opioid
agonists (Figure 2). Similar to other synthetic opioid agonists
such as fentanyl, fentanyl derivatives, and meperidine, the
structure is distinct from morphine which is used as the basis
for opiate detection on most urine drugs of abuse panels.[17]
The laboratory technique we used (LC-TOF), enabled deter-
mination of the molecular formula of the drug used, which
matched U-47700. However, to conclusively identify an
unknown drug without the use of nuclear magnetic reson-
ance (NMR) analysis, a reference standard is required. For
novel psychoactive substances this is challenging as reference
standards may be unavailable, as was the situation in this
case.[18] AH-7921 is a drug in the same structural class as
U-47700, shares the identical molecular formula, and has
been previously described as an opioid of abuse.[5] By
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purchasing a reference standard for AH-7921 and testing it
on our LC-TOF platform, we were able to exclude that it was
the drug used. Although it seems very likely that the drug
identified was U-47700, it is possible that another opioid,
likely in the same structural class, may have been the one
identified. NMR analysis was not utilized for identification. In
our experience it is necessary to have pure compounds for
NMR analysis, and the material supplied by the patient had a
significant amount of a demethylated analog.
The only previous reports of toxicity related to U-47700
appear to be the two recently published forensic cases in
which U-47700 was identified.[10,11] The similarly structured
AH-7921, appears to have emerged prior to U-47700 as a
drug of abuse. Similar to U-47700, AH-7921 was synthesized
in the 1970s but has never been used medically. ‘‘AH’’ refers
to ‘‘Allen and Hanburys’’, the company that patented the
drug.[19] It was first detected in the United Kingdom in July
of 2012 in a sample obtained via the internet.[20] In 2013, it
was identified as a co-ingredient in synthetic cannabinoid
and cathinone products in Japan.[21] The first death associ-
ated with its use was reported in Norway in December of
2012 and subsequently other cases of fatal and non-fatal
Figure 1. (A–D) Ultra performance liquid chromatography (UPLC) and mass spectra for powder used by the patient (labeled U-47700) and AH-7912. (A) UPLC spec-
trum of two independent runs overlaid showing elution powder used (U-47700 with tr¼ 5.36 and another peak at 5.25 min) which was purchased from the internet
and AH-7912 (tr¼ 5.51). (B) High energy spectrum for the elution peak with tr¼ 5.36 corresponding to U-47700. (C) High energy spectrum for the elution peak with
tr¼ 5.25 corresponding to U-47700 minus 14 Da. (D) High energy spectrum for the elution peak with tr¼ 5.51 corresponding to AH-7912.
Table 1. U-47700 Interference with benzodiazepine
immunoassay.
U-47700 powder concentration
(lg/mL)
COBAS 6000
benzodiazepine signal
Blank 805
1 802
10 804
100 844
1000 963
10,000 1110
25,000 1109
Benzodiazepine absorbance value greater than 1000 trig-
gers positive.
Figure 2. Chemical structures of AH-7921 and U-47700.
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toxicities have been described in other countries in
Europe.[20,22,23] To date, it has been described once in the
United States. In that case, a 19-year old was found dead
after using AH-7921, and its presence was confirmed in the
vial he had used it from and in postmortem samples.[24]
Recreational abuse of opioids remains a serious problem.
Synthetic opioids have not accounted for a significant per-
centage of the recent worldwide surge in abuse of novel psy-
choactive substances. However, the recent reports of abuse of
AH-7921, MT-45, and U-47700 highlight the emerging trend
of novel synthetic opioid abuse.
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